

# 肝炎文献リスト\_2026年1月号

岡本宏明

2026-01-1

Gaps in the hepatitis C prenatal and postpartum care cascade: Rationale for treatment in pregnancy

Mendlowitz A B, Flemming J A, Kushner T, Wong W W L, Greenwald Z R, Li W, Chen B, Kwong J C, Masterman C, Capraru C, Feld J J, Biondi M J

Clin Infect Dis ciaf578, Dec 9 [Epub ahead of print] PMID: 41363839

<https://doi.org/10.1093/cid/ciaf578>

C型肝炎の周産期ケアの連携における課題: 妊娠中治療導入の根拠

2026-01-2

Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal

Lens S, Burton A R, Davies J, Locatelli M, Garcia-Lopez M, Pocurull A, Jeffery-Smith A, Novikov N, Fletcher S P, Fornis X, Perez-Del-Pulgar S, Maini M K

Gut 2024-333309, Dec 19 [Epub ahead of print] PMID: 41419306

<https://doi.org/10.1136/gutjnl-2024-333309>

治療中止による B型肝炎再燃時の B細胞免疫動態の追跡

2026-01-3

Optimizing hepatitis C virus testing in the era of point-of-care RNA diagnostics

Helm E W, Kim H N, Greninger A L

J Clin Microbiol e01259-25, Dec 17 [Epub ahead of print] PMID: 41406031

<https://doi.org/10.1128/jcm.01259-25>

迅速 RNA 検査時代における HCV 検査の最適化

2026-01-4

Bioorthogonal click chemistry to visualize an immunogenic HLA-A2-restricted hepatitis B virus epitope in human monocyte-derived dendritic cells

Mostert T P, Kessler A L, Luijten R J, Doelman W, Isendoorn M M E, Filippov D V, van Kasteren S I, Buschow S I

J Immunol vkaf312, Nov 20 [Epub ahead of print] PMID: 41267163

<https://doi.org/10.1093/jimmun/vkaf312>

バイオオルソゴナル・クリック化学による HLA-A2 拘束 HBV エピトープの樹状細胞可視化

2026-01-5

Oral microbiome diversity matters on nucleos(t)ide analogue cessation in chronic hepatitis B

Ghorbani M, Kvedaraitė A, Al-Manei K, Too C B, Cederberg S, Johannessen A, Reikvam D H, Valentini D, Maucourant C, Bjorkstrom N K, Aleman S, Sallberg Chen M

J Infect Dis jiaf591, Dec 2 [Epub ahead of print] PMID: 41328917

<https://doi.org/10.1093/infdis/jiaf591>

B型肝炎核酸アナログ中止時の病勢に関連する口腔微生物叢の多様性

### 2026-01-6

Development of a rapid automated point-of-care test for hepatitis C viral RNA on the DASH® Rapid PCR System

Reed J L, Butzler M A, Hawkins C A, Manabe Y C, Holden J, Thomas D L, Cox A L, McFall S M

J Infect Dis jiaf608, Dec 10 [Epub ahead of print] PMID: 41369203

<https://doi.org/10.1093/infdis/jiaf608>

DASH®迅速 PCR システムを用いた HCV RNA 迅速自動 POC 検査の開発

### 2026-01-7

A rapid assay for HCV RNA detection using RT-LAMP coupled CRISPR-Cas12b based strategy

Chowdhury A, Garcia B G, Zahoor M A, Fadl ElMawla N, Davidson A R, Wyatt H D M, Maxwell K L, Mahassine A, Gehring A, Feld J J

J Infect Dis jiaf609, Dec 16 [Epub ahead of print] PMID:41397899

RT-LAMP と CRISPR-Cas12b を組み合わせた HCV RNA 迅速検出法

### 2026-01-8

Transient interferon-driven NK cell activation in acute hepatitis C

Strunz B, Zhan Q, Khera T, Hengst J, Jankovic M, Deterding K, Niehrs A, Cornberg M, Xu C J, Wedemeyer H, Bjorkstrom N K

J Infect Dis jiaf654, Dec 27 [Epub ahead of print] PMID: 41453396

<https://doi.org/10.1093/infdis/jiaf654>

急性 C 型肝炎における一過性の IFN 依存性 NK 細胞活性化

### 2026-01-9

The differential effects of immunosuppressants on hepatitis E virus replication and the triggered inflammatory responses in macrophages

Zhou J, Liu K, Boor P P C, Pan Q, Ayada I

J Viral Hepat 33(1): e70118, 2026 PMID: 41400072

<https://doi.org/10.1111/jvh.70118>

免疫抑制剤が HEV 複製とマクロファージ炎症応答反応に及ぼす影響

### 2026-01-10

Impact of double reflex testing and linkage to treatment on clinical outcomes of chronic hepatitis delta virus infection in the United States

Wong R J, Gish R G, Jacobson I M, Lim J K, Rock M, Kinyik-Merena C, Ma H, Smith N, Kim C

J Viral Hepat 33(1): e70119, 2026 PMID: 41405233

<https://doi.org/10.1111/jvh.70119>

二段階リフレックス検査と治療連結が米国の HDV 感染予後に与える影響

**2026-01-11**

The current burden of hepatitis B in the United States: A state, territorial, and county modelling analysis

Razavi-Shearer D, Gamkrelidze I, Hall S, Cohen C, Gish R, Pham T, Razavi-Shearer K, Remak W, Saboui M, Voeller A, Wallace C, Razavi H

J Viral Hepat 33(1): e70122, 2026

PMID: 41416586

<https://doi.org/10.1111/jvh.70122>

米国における B 型肝炎の現状負担: 州、準州、郡レベルのモデリング解析

**2026-01-12**

Molecular insights into the S gene of hepatitis B virus: Analysis among household contacts and clinical implications of mutations

Athalye S, Khargekar N, Panale P, Shinde S, Shankarkumar A, Banerjee A

J Viral Hepat 33(1): e70124, 2026

PMID:41424401

HBV S 遺伝子の分子レベルでの知見: 同居家族内解析と変異の臨床的意義

**2026-01-13**

GRP75 blocks hepatitis E virus infection by targeting HEV-ORF2 for degradation through chaperone-mediated autophagy and promoting IRF3 activation

Wang Y, Li Y, Xu R, Yuan T, Xu C, Zhou Z, Ba C, Zhao Q, Wu C, An Z, Yin X, Yang Y, Nan Y

J Virol e01344-25, Dec 17 [Epub ahead of print]

PMID: 41405201

<https://doi.org/10.1128/jvi.01344-25>

GRP75 はシャペロン介在性オートファジーで HEV-ORF2 の分解し、IRF3 活性化を促して HEV 感染を抑制

**2026-01-14**

A Phase 2 trial of tobevibart plus elebsiran in hepatitis D

Asselah T, Chattergoon M A, Jucov A, Streinu-Cercel A, Lampertico P, Wedemeyer H, Kennedy P T, Gane E J, Bullard B L, Chow S, Santos D, Camus G, Lu Y, Pilowa C, Hwang C, Correll T, Agarwal K

N Engl J Med oa2508827, Nov 9 [Epub ahead of print]

PMID:41211943

D 型肝炎に対するトベビバートとエレブシランの併用療法の第 2 相試験

**2026-01-15**

Netrin-1 inhibits the attachment and internalization of hepatitis B virus for hepatocyte infection

Wang Y, Murai K, Ishida A, Kawasaki N, Kuroki K, Li Y Y, Sato Y, Miura Y, Takara K, Kong L, Shimakami T, Nio K, Higuchi Y, Suemizu H, Ito S, Yanagawa H, Kaneko S, Yamashita T, Honda M

PLoS Pathog 21(12): e1013776, 2025

PMID: 41406170

<https://doi.org/10.1371/journal.ppat.1013776>

ネトリン-1 は HBV の肝細胞への接着と侵入を抑制

**2026-01-16**

Structural insights into the role of eIF3 in translation mediated by the HCV IRES

Iwasaki W, Kashiwagi K, Sakamoto A, Nishimoto M, Takahashi M, Machida K, Imataka H, Matsumoto A, Shichino Y, Iwasaki S, Imami K, Ito T

Proc Natl Acad Sci U S A 122(49): e2505538122, 2025 PMID:41337487

[HCV IRES 介在翻訳における eIF3 の役割: 構造学的解析](#)

**2026-01-17**

The prion-like characteristic of ORF3 contributes to virion release and pathogenesis of hepatitis E virus

Wang Y, Tian H, Shi N, Wu C, Huang Y, Yang Y, Ding Q, Zheng X, Zhao Q, Hu Z, Luo J, Feng L, Xu L, Tuite M F, Chen H, Nan Y

Proc Natl Acad Sci U S A 122(49): e2511801122, 2025 PMID:41343667

[HEV ORF3 タンパク質のプリオン様特性が粒子放出と病原性に関与](#)

**2026-01-18**

Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection

He Y, Zhong L, DeSilva A R, Kwok K S, Deng L, Virata M L, Yan H, Scott D, Major M, Alter H J, Zhang P

Proc Natl Acad Sci U S A 123(1): e2522340122, 2026 PMID:41481431

[HCV E2 高保存ペプチドへの抗体応答は慢性化/自然排除と相関](#)

**2026-01-19**

Challenges in accurate HDV RNA quantification: inter-assay variability and the impact of thermal shock

Perez-Garcia F, Virseda-Berdices A, Pita-Martinez C, Munoz Monte M, Sepulveda-Crespo D, Codina H, Alonso R, Mesones L, Rodrigo S, Macias J, Real L M, Cuadros-Gonzalez J, Martinez I, Resino S

J Clin Microbiol e01517-25, Dec 31 [Epub ahead of print] PMID: 41474328

<https://doi.org/10.1128/jcm.01517-25>

[HDV RNA 定量の課題: 測定系間のばらつきと熱ショックの影響](#)

**2026-01-20**

Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent

Mimms J L, Sinnis-Bourozikas A, Felbinger N R, Frumento N, Paul H T, Patel A H, Keck Z, Fong S K H, Law M, Urbanowicz R A, Tarr A W, Ball J K, Pierce B G, Bailey J R

J Gen Virol 107(1):002201, 2026 PMID: 41527886

<https://doi.org/10.1099/jgv.0.002201>

[HCV E1E2 中和部位の抗原性は遺伝子型非依存](#)

**2026-01-21**

The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators

Askari F S, Mohebbi A

Sci Rep 15:32731, 2025

PMID: 40993170

<https://doi.org/10.1038/s41598-025-18339-6>

各種カプシド組立調節薬が与える HBV カプシドモノマーの動的状態

**2026-01-22**

Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with tenofovir alafenamide vs. entecavir

Kim H, Kim J Y, Yoo H J, Kim L Y, Yoo J J, Kim S G, Kim Y S

Sci Rep 15:33872, 2025

PMID: 41028032

<https://doi.org/10.1038/s41598-025-08023-0>

慢性 B 型肝炎での TAF と ETV の腎予後比較:全国データ

**2026-01-23**

Bioinformatics identification of key genes correlating NOD1 and Endoplasmic reticulum stress in hepatitis B virus-induced acute liver failure

Deng F, Jiang W, Wang N, Wu Y, Xu J, Hou R, Jia F

Sci Rep 15:35919, 2025

PMID: 41087615

<https://doi.org/10.1038/s41598-025-19813-x>

HBV-ALF での NOD1 と小胞体ストレスを結ぶ鍵遺伝子のバイオインフォ解析

**2026-01-24**

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort

Suda G, Baba M, Yamamoto Y, Yoshida S, Muranaka T, Meguro T, Terashita K, Ito J, Kobayashi T, Izumi T, Takagi T, Hosoda S, Yamada R, Fu Q, Yang Z, Yokoyama D, Tanaka T, Meno A, Yasuura N, Kitagataya T, Ohara M, Kawagishi N, Nakai M, Sho T, Ogawa K, Sakamoto N

Sci Rep 15:42628, 2025

PMID: 41315792

<https://doi.org/10.1038/s41598-025-26891-4>

日本人慢性 C 型肝炎患者における SOF/VEL 治療のモニタリング簡素化:前向き多施設コホートの後ろ向き解析

**2026-01-25**

Identification of key biomarkers associated with necroptosis and immune infiltration in hepatitis B virus-related acute-on-chronic liver failure

Cao C, Luo D, Xie X, Dou C

Sci Rep 15:37440, 2025

PMID: 41145553

<https://doi.org/10.1038/s41598-025-21273-2>

HBV-ACLF におけるネクロプトーシスと免疫浸潤の鍵バイオマーカー

**2026-01-26**

Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B  
He T, Chen M, Liu M, Zhang L, Sun H, Zhang L, Li A, Zeng W, Ling N, Shi X, He H, Peng M, Cai D, Hu P, Zhang D, Lan Y, Ren H

Gut 2025-336655, Dec 24 [Epub ahead of print] PMID:41443982

24週間の抗PD-1抗体治療でHBsAg低下とHBV特異的T細胞応答の増強

**2026-01-27**

Circulating HBV RNA and HBsAg seroconversion in patients with chronic HBV infection: a long-term follow-up study starting from childhood in Taiwan

Wu J F, Hsu C T, Tai C S, Chang K C, Chu C Y, Chiu Y C, Chen H L, Ni Y H, Chang M H

Gut 2025-337123, Dec 19 [Epub ahead of print] PMID:41419305

小児期からの長期追跡でみた血中HBV RNAとHBsAgセロコンバージョン:台湾コホート

**2026-01-28**

Epidemiology and clinical characteristics of rat hepatitis E virus infection in humans

Situ J, Wong T C, Wu S, Li Z, Shun E H K, Ho S F S, Yip C C Y, Lo K H Y, Tsoi J Y H, Ma W, Lo A T K, Yiu J, Ng E Y T, Kwong M Y, Ip C Y L, Chung H L, Chew N F S, Liang Y, Mao W, Ma X, Hui D T Y, Wong S C Y, Chan K M, Cheung C Y, Kwong T S, Lung D C, Cheng V C C, Yuen K Y, Sridhar S

J Infect 92(1):106667, 2026

PMID:41421648

ヒトにおけるラットHEV感染の疫学と臨床的特徴

**2026-01-29**

Immunological characterization of hepatitis B core antigen antibody among vaccinated adults lacking hepatitis B surface antigen in Ethiopia: A multicenter facility-based study

A dugna A, Abebaw D, Teffera Z H, Kindie Y, Belay W Y, Mihiret G T, Kassaw A B, Abera M B, Abebe G, Alem A, Geto Z, Seid M A, Yesuf H A, Asfaw M S, Jemal M

Sci Rep 15:41052, 2025

PMID: 41266567

<https://doi.org/10.1038/s41598-025-25018-z>

エチオピアのHBVワクチン接種成人(HBs抗原陰性)におけるHBc抗体の免疫学的特徴

**2026-01-30**

Network pharmacology and molecular docking reveal antiviral mechanisms of silver nanoparticles synthesized by *Oscillatoria* sp. against HCV pathogenesis

Azmy L, Al-Olayan E, Abdelhamid M A A, Ibraheem I B M, Zayed A, Gheda S F, Youssif K A, Abou-Zied H A, Abdelmohsen U R, Pack S P, Khalifa H O, Elsayed K N M

Sci Rep 15:43891, 2025

PMID: 41387476

<https://doi.org/10.1038/s41598-025-26310-8>

藍藻由来銀ナノ粒子の抗HCV作用機序:ネットワーク薬理と分子ドッキング解析

**2026-01-31**

Serum osteocalcin is associated with the presence of hepatic steatosis in Chinese patients with chronic hepatitis B

He Y, Tong L, Zhou Y, Xie F, Tian N, Xie W

Sci Rep 15:41641, 2025

PMID: 41285914

<https://doi.org/10.1038/s41598-025-25625-w>

慢性 B 型肝炎の中国人患者で血清オステオカルシンは脂肪肝の存在と関連

**2026-01-32**

Genomic surveillance of HBV and HDV reveals genotype-specific risk of liver disease in central Vietnam

Cao L C, Xinh T T T, Phuoc D N, Dung N T, Loan T T K, Van Duc P, Huyen D T, Linh L T K, Song L H, Velavan T P

Sci Rep 15:43491, 2025

PMID: 41372328

<https://doi.org/10.1038/s41598-025-31423-1>

ベトナム中部での HBV/HDV ゲノムサーベイランス: 遺伝子型別の肝疾患リスク

**2026-01-33**

Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis

Yang Y, Xing H, Wu G, Zhao Y

Sci Rep 15:44244, 2025

PMID: 41422317

<https://doi.org/10.1038/s41598-025-23207-4>

HBc 抗体陽性者における occult HBV 感染(OBI)の世界有病率: 系統的レビューとメタ解析

**2026-01-34**

Metabolic dynamics and stage-specific biomarkers in chronic HBV infection: a metabolomics study

Liu L, Zhu Z, Jin W, Su X, Deng Z, Li C

BMC Gastroenterol 25:744, 2025

PMID: 41120959

<https://doi.org/10.1186/s12876-025-04332-w>

慢性 HBV 感染における代謝動態と病期別バイオマーカー: メタボロミクス研究

**2026-01-35**

Serology change-based clinical interpretation of indeterminate serostatus post-hepatitis B virus infection in people living with HIV

Kinai E, Ishikura M, Miyashita R, Yamaguchi T, Chikasawa Y, Ichiki A, Sekiya R, Bingo M, Muramatsu T, Yotsumoto M, Hagiwara T, Amano K

PLoS One 20(11): e0336924, 2025

PMID: 41264590

<https://doi.org/10.1371/journal.pone.0336924>

HIV 感染者における HBV 既感染後の不確定血清学的所見の解釈: 経時変化に基づく臨床判断

**2026-01-36**

Viral surveillance of invasive mammals in New Zealand reveals unique viral lineages reflecting their introduction history

French R K, Pichlmüller F, Waller S J, Dubrulle J, Tuxford J, Veale A, Geoghegan J L  
J Virol e01440-25, Dec 19 [Epub ahead of print] PMID: 41416836

<https://doi.org/10.1128/jvi.01440-25>

ニュージーランドにおける外来哺乳類のウイルス監視: 導入史を反映する固有系統の発見

**2026-01-37**

Hepatitis E virus screening in Irish blood donors: Seven years of individual donation nucleic acid testing reveals a frequent blood donor infection-but what is the risk?

O'Flaherty N, Mullarkey M, Burke L, Williams P, Dean J, Szulc J, Waters A  
Transfus Med 70047, Dec 12 [Epub ahead of print] PMID: 41386707

<https://doi.org/10.1111/tme.70047>

アイルランド献血者における HEV スクリーニング: 7 年の個別 NAT で判明した感染頻度とリスク評価

**2026-01-38**

Immune memory assessment three years following a single dose of hepatitis A vaccine at 12, 13 or 19 months of age

Febriani Y, Ursu M M, Sauvageau C, Kegbevi K B, Quach C, Desjardins M, Bestman-Smith J, Gilca V, Brousseau N  
Vaccine 73:128144, 2026 PMID: 41453243

<https://doi.org/10.1016/j.vaccine.2025.128144>

12・13・19 ヶ月時の単回 A 型肝炎ワクチン接種後 3 年の免疫記憶評価

**2026-01-39**

Optimization of lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes for *in vivo* delivery of a CRISPR/Cas9 system targeting hepatitis B virus

Akhter R, Kitab B, Kayesh M E H, Shimizu R, Onuma H, Yamamoto N, Ogawa S, Sugiyama M, Tanaka Y, Sato Y, Kohara M, Tsukiyama-Kohara K  
Virus Res 363:199682, 2026 PMID: 41453683

<https://doi.org/10.1016/j.virusres.2025.199682>

HBV 標的 CRISPR/Cas9 送達のためのリボ核タンパク質-オリゴヌクレオチド複合体搭載 LNP の最適化

**2026-01-40**

Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis

Yang S, Lin Y, Zhang H, Liang Y, Yuan W, Wang X, Lin W, Hong W, Su Z, Zeng D, Yu X  
BMC Gastroenterol 25:760, 2025 PMID: 41136921

<https://doi.org/10.1186/s12876-025-04289-w>

慢性 B 型肝炎に対する TDF・TAF・TMF および TDF→TAF 切替の有効性: ネットワークメタ解析

**2026-01-41**

Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma

Ma Y, Lou C, Liang J, Guo C, Zhang J, Lu C, Zhang J, Gao Y  
BMC Cancer 25:1768, 2025

PMID: 41239305

<https://doi.org/10.1186/s12885-025-15237-y>

HBV 関連肝癌の進展で変動する細胞外小胞由来 lncRNA の特徴

**2026-01-42**

Pangenotypic glecaprevir/pibrentasvir therapy for chronic hepatitis C in children

Pawlowska M, Zarebska-Michaluk D, Dobrowolska K, Moppert J, Kalinowska Z, Pokorska-Spiewak M, Mania A, Majda-Stanislawski E, Flisiak R

Pediatr Infect Dis J 005069, Nov 20 [Epub ahead of print] PMID:41261401

小児慢性 C 型肝炎に対する全ゲノタイプ対応 GLE/PIB 療法

**2026-01-43**

Genetic influence of IFN- $\gamma$  gene polymorphisms on hepatitis C progression and recovery

Rafiq K, Khan S, Khan M B, Yaqoob M, Adnan M

J Virol Methods 342:115337, 2026

PMID:41506323

IFN- $\gamma$  遺伝子多型が C 型肝炎の進行と回復に及ぼす影響

**2026-01-44**

Hepatitis B virus genomic variability & HBV-related disease outcomes: A molecular epidemiology perspective

Bousali M, Papatheodoridis G, Bletsas M, Paraskevis D, Karamitros T

J Med Virol 97(12): e70760, 2025

PMID: 41424412

<https://doi.org/10.1002/jmv.70760>

HBV ゲノム多様性と疾患転帰: 分子疫学的考察

**2026-01-45**

Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C

Li J, Yangjin B, Zhu C, Xu W, He Y

BMC Gastroenterol 25:860, 2025

PMID: 41398933

<https://doi.org/10.1186/s12876-025-04412-x>

C 型肝炎抗ウイルス治療後の長期 HCC リスク予測ノモグラムの開発

**2026-01-46**

Coexistence of HBsAg and anti-HBs predicts severe hepatic fibrosis in untreated children with hepatitis B virus infection

Yao Z, Gu Y, Lai X, Luo J, Peng S

J Med Virol 97(12): e70763, 2025

PMID:41420401

未治療小児 HBV 感染での HBsAg・抗 HBs 同時陽性は重度線維化の予測因子

### 2026-01-47

The ratio of GGT to PLT indices is a predictive factor for the progression of liver fibrosis in NA-treated chronic hepatitis B patients with advanced fibrosis plus PEG-IFN  $\alpha$ -2a therapy: a case-control study

Li L, Li H, Zhao Y, Shi L, Suwanbai M, Ren L, Li G, Pan X

BMC Gastroenterol 2025-04508-4, Dec 10 [Epub ahead of print] PMID: 41372812

<https://doi.org/10.1186/s12876-025-04508-4>

高度線維化 CHB の NA + PEG-IFN $\alpha$ -2a 治療で GGT/PLT 比 (GPR) は線維化進展の予測因子

### 2026-01-48

Low-level viremia increases the risk of adverse long-term outcomes in entecavir-treated patients with chronic hepatitis B

Ji D, He M W, Wang W C, Han W, Chen Y, Liu Y, Li L, Li X Y, Guo Y F, Yang W C, Dong Z, Wang C Y, Xu J, Tan L, Lau G, Yang Y

Antiviral Res 246:106334, 2026

PMID:41412547

ETV 治療中の低レベルウイルス血症は長期転帰不良リスクを増加

### 2026-01-49

Spatial variation in risk factors for anti-hepatitis E antibody titers in a population-based German study

Diaz A C, Ittermann T, Nauck M, Petersmann A, Volzke H, Schauer B

Sci Rep 15:41463, 2025

PMID: 41272160

<https://doi.org/10.1038/s41598-025-26850-z>

ドイツ住民ベース研究における HEV 抗体価リスク因子の地域差

### 2026-01-50

Unraveling a mechanism underlying hepatitis E-associated kidney disease: Discovery of HEV ORF2 capsid protein-associated immune complex glomerulonephritis

Leblond A L

Pathologie (Heidelb) 47(Suppl 1): S27-31, 2026

PMID: 41284019

<https://doi.org/10.1007/s00292-025-01499-7>

E 型肝炎関連腎疾患の発症メカニズムの解明: HEV ORF2 カプシドタンパク質関連免疫複合体糸球体腎炎の発見

### 2026-01-51

Immunogenicity and safety of HepE Hecolin<sup>®</sup> in chronic hepatitis B patients at clinically stable stage: An open-label study in China

Zhang L, Zhang Q, Liu J, Wu W, Jiang Z, Yan B, Cao Q, Liu H, Pan H, Lv J, Feng Y, Xu F, Huang S, Xu A

Hum Vaccin Immunother 21(1):2448882, 2025

PMID: 39797410

<https://doi.org/10.1080/21645515.2024.2448882>

臨床的に安定した慢性 B 型肝炎患者における Hecolin<sup>®</sup> (HEV ワクチン) の免疫原性と安全性: 中国オープンラベル試験

**2026-01-52**

Multiplex serological screening of wild boar as sentinels of emerging zoonoses: HEV, WNV, and TBEV distribution in Saxony, Germany

Kasper L, Sadeghi B, Deutschmann P, Stoek F, Ziegler U, Balkema-Buschmann A, Groschup M H, Eiden M

One Health 21:101283, 2025

PMID: 41368441

<https://doi.org/10.1016/j.onehlt.2025.101283>

新興人獣共通感染症の指標としてのイノシシ:HEV/WNV/TBEV の多重血清スクリーニング(ドイツ、ザクセン州)

**2026-01-53**

Beyond burden: a Quality of Care Index (QCI) assessment of hepatitis B in 204 countries, 1990-2021

Hu Y, Qi X, Jiang Y, Jiang W

Virus Res 364:199683, 2026

PMID: 41485714

<https://doi.org/10.1016/j.virusres.2025.199683>

疾病負担だけでなくケアの質を見る: HBV 診療の質指標(QCI)による 204 か国評価(1990-2021)

**2026-01-54**

Viral hepatitis as a differential diagnosis of yellow fever suspected cases in Cameroon: Prevalence and molecular characterization

Modiyinji A F, Simo H T, Mounchili-Njifon A, Moumbeket-Yifomnjou M H, Djomo L F, Yabi D N, Odi J G, Machuetum G L, Ngu A N, Njouom R

IJID Reg 17:100732, 2025

PMID: 41473503

<https://doi.org/10.1016/j.ijregi.2025.100732>

カメルーンの黄熱疑い例における鑑別としてのウイルス性肝炎: 有病率と分子生物学的特徴

**2026-01-55**

Efficacy of DPMAS combined with PE in improving survival outcomes of patients with acute hepatitis E-induced liver failure: A retrospective cohort analysis

Tang R, Ji Y, Yao H, Zhou X, Feng D, Cheung E C, Liu H, Wang K

iLIVER 4(4):100203, 2025

PMID: 41362691

<https://doi.org/10.1016/j.iliver.2025.100203>

急性 E 型肝炎誘発性肝不全での DPMAS + PE の有効性: 後ろ向きコホート分析

**2026-01-56**

No evidence of hepatitis E virus-associated central nervous system infections in a Vietnamese multicenter cohort

Dong D V, Sang V V, Hoan N X, Linh N T K, Quang H X, Lien T T, Trang V D, Song L H, Velavan T P

IJID Reg 17:100793, 2025

PMID: 41280343

<https://doi.org/10.1016/j.ijregi.2025.100793>

ベトナム多施設コホートにおいて HEV 関連中枢神経系感染症の証拠なし

**2026-01-57**

Patagonian shellfish and hidden threats: unveiling the viral landscape and the first quantitative microbial risk assessment of Argentine bivalve mollusks

Frydman C, Parreño V, Cap M, Galeano S, Signorini Porchietto M, Mozgovej M

Food Microbiol 135:104981, 2026

PMID:41344773

パタゴニア産貝類に潜む脅威: ウイルス分布の解明と初の定量的微生物リスク評価

**2026-01-58**

Innate and adaptive immune responses in hepatitis C virus infections

Kishida Y

Virus Res 364:199685, 2026

PMID: 41500336

<https://doi.org/10.1016/j.virusres.2026.199685>

HCV 感染における自然免疫と獲得免疫応答

**2026-01-59**

Epidemiology and seroprevalence of hepatitis E Virus in Nigeria and its African context: a review and one health perspective

Olowu B I, Tinubu O B, Solesi O O, Ochi E, Ahmed S O, Zakariya M E

Infez Med 33(4):370-81, 2025

PMID: 41384158

<https://doi.org/10.53854/liim-3304-2>

ナイジェリアの HEV 疫学と抗体保有率: アフリカの実情とワンヘルス視点

**2026-01-60**

Hepatitis E virus in immunocompromised children in Argentina: first report from a high-risk group

Acosta J, Costaguta G, Gardiol D, Álvarez F, Costaguta A, Cavatorta A L

Virology 23:2, 2026

PMID: 41331869

<https://doi.org/10.1186/s12985-025-03037-6>

アルゼンチンの免疫不全児における HEV 感染: 高リスク群からの初報